血浆成纤维细胞生长因子 21 与缺血性中风患者认知障碍的风险。

IF 2.9 3区医学 Q2 NEUROSCIENCES

Neuroscience Pub Date : 2024-11-12 DOI:10.1016/j.neuroscience.2024.11.012

Xiaowei Zheng , Zhengbao Zhu , Chongke Zhong , Daoxia Guo , Xiaoqing Bu , Hao Peng , Tan Xu , Yonghong Zhang

{"title":"血浆成纤维细胞生长因子 21 与缺血性中风患者认知障碍的风险。","authors":"Xiaowei Zheng , Zhengbao Zhu , Chongke Zhong , Daoxia Guo , Xiaoqing Bu , Hao Peng , Tan Xu , Yonghong Zhang","doi":"10.1016/j.neuroscience.2024.11.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Previous study reported that plasma fibroblast growth factor 21 (FGF-21) was associated with poor prognosis in patients with ischemic stroke. The purpose of present study was to prospectively investigate the relationship between plasma FGF-21 and post-stroke cognitive impairment (PSCI).</div></div><div><h3>Methods</h3><div>A total of 600 patients from 7 hospitals were included in this study and plasma FGF-21 levels were examined for all the participants. Cognitive impairment was evaluated using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) at 3 months after ischemic stroke onset.</div></div><div><h3>Results</h3><div>323(53.8 %) or 419(69.8 %) participants had PSCI according to MMSE or MoCA at 3 months, respectively. After adjustment for age, National Institutes of Health stroke score, education, and other covariates, the odds ratio of PSCI defined by MMSE and MoCA for the highest vs lowest quartile of plasma FGF-21 was 1.77(1.05–2.98) and 2.40(1.35–4.29), respectively. Multiple-adjusted spline regression model showed a linear association between FGF-21 levels and PSCI (all <em>P</em> < 0.005 for linearity). Subgroup analyses further confirmed these results.</div></div><div><h3>Conclusion</h3><div>Elevated plasma FGF-21 level was associated with PSCI at 3 months after stroke independently of established conventional risk factors, suggesting that plasma FGF-21 may have potential prognostic value in risk stratification of PSCI.</div></div>","PeriodicalId":19142,"journal":{"name":"Neuroscience","volume":"563 ","pages":"Pages 129-135"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma fibroblast growth factor 21 and risk of cognitive impairment among patients with ischemic stroke\",\"authors\":\"Xiaowei Zheng , Zhengbao Zhu , Chongke Zhong , Daoxia Guo , Xiaoqing Bu , Hao Peng , Tan Xu , Yonghong Zhang\",\"doi\":\"10.1016/j.neuroscience.2024.11.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aims</h3><div>Previous study reported that plasma fibroblast growth factor 21 (FGF-21) was associated with poor prognosis in patients with ischemic stroke. The purpose of present study was to prospectively investigate the relationship between plasma FGF-21 and post-stroke cognitive impairment (PSCI).</div></div><div><h3>Methods</h3><div>A total of 600 patients from 7 hospitals were included in this study and plasma FGF-21 levels were examined for all the participants. Cognitive impairment was evaluated using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) at 3 months after ischemic stroke onset.</div></div><div><h3>Results</h3><div>323(53.8 %) or 419(69.8 %) participants had PSCI according to MMSE or MoCA at 3 months, respectively. After adjustment for age, National Institutes of Health stroke score, education, and other covariates, the odds ratio of PSCI defined by MMSE and MoCA for the highest vs lowest quartile of plasma FGF-21 was 1.77(1.05–2.98) and 2.40(1.35–4.29), respectively. Multiple-adjusted spline regression model showed a linear association between FGF-21 levels and PSCI (all <em>P</em> < 0.005 for linearity). Subgroup analyses further confirmed these results.</div></div><div><h3>Conclusion</h3><div>Elevated plasma FGF-21 level was associated with PSCI at 3 months after stroke independently of established conventional risk factors, suggesting that plasma FGF-21 may have potential prognostic value in risk stratification of PSCI.</div></div>\",\"PeriodicalId\":19142,\"journal\":{\"name\":\"Neuroscience\",\"volume\":\"563 \",\"pages\":\"Pages 129-135\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0306452224005943\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306452224005943","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

背景与目的：先前的研究报道血浆成纤维细胞生长因子21（FGF-21）与缺血性卒中患者的不良预后有关。本研究旨在前瞻性地探讨血浆成纤维细胞生长因子 21 与脑卒中后认知障碍（PSCI）之间的关系：本研究共纳入了来自 7 家医院的 600 名患者，并对所有参与者的血浆 FGF-21 水平进行了检测。缺血性脑卒中发病 3 个月后，使用迷你精神状态检查（MMSE）和蒙特利尔认知评估（MoCA）对认知障碍进行评估：根据 3 个月时的 MMSE 或 MoCA，分别有 323 人（53.8%）或 419 人（69.8%）患有 PSCI。在对年龄、美国国立卫生研究院卒中评分、教育程度和其他协变量进行调整后，血浆 FGF-21 的最高四分位数与最低四分位数在 MMSE 和 MoCA 中定义的 PSCI 的几率比分别为 1.77（1.05-2.98）和 2.40（1.35-4.29）。多重调整曲线回归模型显示，FGF-21水平与PSCI之间存在线性关系（均为P 结论：血浆FGF-21水平升高与PSCI之间存在线性关系：血浆 FGF-21 水平升高与卒中后 3 个月的 PSCI 相关，而与既定的常规风险因素无关，这表明血浆 FGF-21 在 PSCI 风险分层中可能具有潜在的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Plasma fibroblast growth factor 21 and risk of cognitive impairment among patients with ischemic stroke

Background and aims

Previous study reported that plasma fibroblast growth factor 21 (FGF-21) was associated with poor prognosis in patients with ischemic stroke. The purpose of present study was to prospectively investigate the relationship between plasma FGF-21 and post-stroke cognitive impairment (PSCI).

Methods

A total of 600 patients from 7 hospitals were included in this study and plasma FGF-21 levels were examined for all the participants. Cognitive impairment was evaluated using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) at 3 months after ischemic stroke onset.

Results

323(53.8 %) or 419(69.8 %) participants had PSCI according to MMSE or MoCA at 3 months, respectively. After adjustment for age, National Institutes of Health stroke score, education, and other covariates, the odds ratio of PSCI defined by MMSE and MoCA for the highest vs lowest quartile of plasma FGF-21 was 1.77(1.05–2.98) and 2.40(1.35–4.29), respectively. Multiple-adjusted spline regression model showed a linear association between FGF-21 levels and PSCI (all P < 0.005 for linearity). Subgroup analyses further confirmed these results.

Conclusion

Elevated plasma FGF-21 level was associated with PSCI at 3 months after stroke independently of established conventional risk factors, suggesting that plasma FGF-21 may have potential prognostic value in risk stratification of PSCI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neuroscience 医学-神经科学

CiteScore

6.20

自引率

0.00%

发文量

394

审稿时长

52 days

期刊介绍： Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details.